NCT04994093Completed
Creating an Innovative AI-based Technology TCRact for Designing and Optimizing T-cell Receptors (TCR) for Use in Cancer Immunotherapies
Creating an Innovative AI-based (Artificial Intelligence) IN SILICO TECHNOLOGY TCRact to Launch a NEW SERVICE for Designing and Optimizing T-cell Receptors (TCR) for Use in Cancer Immunotherapies
Source: ClinicalTrials.gov · Last updated 26 Jun 2024
Brief summary (registry, in English)
The PROJECT OBJECTIVE is to create an innovative AI-based (Artificial Intelligence) IN SILICO TECHNOLOGY for the design and optimization of T-cell receptors (TCRs) capable of recognizing specific tumor antigens presented on Human Leukocyte Antigen (HLA). The technology will be based on bioinformatics (including molecular modelling) and artificial intelligence (including predictive, generative and optimization models). PROJECT TASKS are dedicated to the implementation of individual technological components (including the database necessary for their preparation) and to performing IN VITRO evaluation rounds to optimize the technology. Integration, within an IN SILICO TECHNOLOGY, of processes which currently require huge amounts of in vitro laboratory experiments that are necessary for bringing new TCR-based cancer immunotherapies into clinical trials: * finding appropriate TCRs targeting cancer neoantigen presented on a HLA molecule (pHLA) * testing for potential TCR toxicity (targeting self antigens presented on healthy tissues) * optimization of pHLA:TCR binding affinity and toxicity.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 118 (actual)
- First submitted
- 29 Jul 2021
- Start date
- 6 Oct 2021
- Primary completion date
- 5 Dec 2022
- Lead sponsor
- Ardigen
- Diseases
- Colorectal cancer
- NCT number
- NCT04994093
What you commit to
- Study type: Observational
- Participants enrolled: 118
- From 6 Oct 2021 to the primary completion date, 5 Dec 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients treated with neoadjuvant therapy or radiation therapy in the 3 months prior to study enrollment.
- Patients treated with systemic chemotherapy in the 3 months prior to study enrollment.
Other illness
- Canal and anal edge cancer,
- History of inflammatory bowel diseases
- HIV infection
- Active infection with hepatitis B and C viruses
Other
- Mucinous colorectal adenocarcinoma
- Adenocarcinoma of the appendix,
- Histopathological diagnosis other than adenocarcinoma
- Remission
- Pregnancy
- Leukocytopenia
Who the study is looking for
- Clinical diagnosis of advanced resectable colorectal cancer (Active stage II, III or IV)
- Histopathologically confirmed as adenocarcinoma
- Age 18 or over
- Being able to understand and sign the Informed Consent Form (ICF)
- Qualification for resection within 3 months from W0 or condition after primary tumor resection, not longer than 5 years from surgery
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Maria Sklodowska-Curie National Research Institute of Oncology Coordinator of this site? Confirm its status | Krakow | Poland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.